States Take Initiative as Trump Overlooks Medicaid Coverage for GLP-1 Obesity Treatments

When Page Campbell’s physician suggested Wegovy, an injectable weight loss drug, prior to her bariatric surgery, she was eager to try it. "I’ve battled my weight for so long,” expressed Campbell, 40, a single mother of two. After about four weeks on Wegovy, she reported no adverse effects but remained unaware of her weight loss progress since skipping home scales. Confident and committed, she noted, “I’m changing my eating habits and exercising.” Wegovy, part of the costly GLP-1 drug category, offers a lifeline to many struggling with obesity, yet remains inaccessible to numerous potential users due to high costs and insurance exclusions. As health experts recognize its potential, access barriers remain a significant issue for countless individuals seeking effective weight loss solutions.